Cross Road Biotech Inversiones Biotecnológicas (CRB Inverbío SGECR SA) is a venture capital management firm registered with number 87 in the CNMV. CRB Inverbío manages Venture Capital Firms that invest in the development of seed stage companies in life sciences that address unmet medical needs and have the potential to grow into successful businesses. To that end, the company selects innovative projects led by prestigious scientists and entrepreneurs, providing financing, management support and strategic advice.
CRB Inverbío is based upon the expertise and successful track record in continuous value creation of Cross Road Biotech, a Spanish venture capital firm that has invested and managed eleven biotech companies since 2005. CRB Inverbío has a unique competitive advantage: the expertise, analytical capabilities and commitment to succeed of the management team: a key element to build highly successful businesses and maximize the returns to the investors.
CRB Inverbío manages Funds and Venture Capital Firms specialized in life sciences. At present the company is launching CRB Bio II, a 60M€ venture capital fund to invest in emerging companies for life sciences, an attractive opportunity to participate in one of the most powerful investment sector of the new economy.
Enrique Castellón
President
Ángel Santos
Director of Business Development
Pablo Cabello
Technical and Scientific Director
Manuel Castellón
General Director
CRB Inverbío manages Venture Capital Firms that invest in the development of seed stage companies in life sciences that address unmet medical needs and have the potential to grow into successful businesses.
In Spain, Biotech companies specialized in life Sciences are underfinanced compared to its European or US peers. This is due to the limited private capital available for investment in the industry. There are also other reasons:
Although as a strategy CRB Inverbío will seek to attract other investors to its participated companies, it is important to ensure that the new Fund has resources to support its investments throughout successive investment follow-on rounds if necessary.
CRB Inverbío has the experience and know how in the Spanish venture capital market specialized in life sciences of the Management Team, led by Enrique Castellón that adds value since the beginning.
Biotechnologycal companies
CRB Health Tech realiza el primer cierre de su fondo en salud digital con Sanitas como inversor de referencia
CRB Inverbío SA SGECR
Nace el primer fondo dedicado a la Salud Digital en España
CRB Inverbío SA SGECR
Aglaris Secures Major Funding to Drive Commercialisation of Ground- breaking Cell-based Therapy Manufacturing System
CRB Inverbío SA SGECR
CRB Inverbío y Progenika refuerzan Mecwins con 4 millones de euros
CRB Inverbío SA SGECR
Nuubo System, creadora de un innovador dispositivo para el diagnóstico de arritmias cardíacas, entra en EEUU
CRB Inverbío SA SGECR
El hospital CIMA Sanitas, primer hospital privado de Cataluña en utilizar el test OWLiver® para el diagnóstico no invasivo del hígado graso
CRB Inverbío SA SGECR
CIC bioGUNE y OWL Metabolomics participan en un innovador proyecto de investigación europeo para desarrollar una mejor prueba diagnóstica de la enfermedad hepática
CRB Inverbío SA SGECR
IDEN Biotechnology se asocia con J.R. Simplot Company para el descubrimiento de genes para la mejora de la patata
CRB Inverbío SA SGECR
Tierra Agrotech and Iden Biotechnology create Joint Venture "Tidas Agrotech" for biologicals commercialiation in India
CRB Inverbío SA SGECR
Aglaris recibe el premio Actualidad Económica a una de las 100 mejores ideas
CRB Inverbío SA SGECR
